

# Treatment for women with postpartum iron deficiency anaemia (Review)

Dodd J, Dare MR, Middleton P



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2007, Issue 4

<http://www.thecochranelibrary.com>



## TABLE OF CONTENTS

ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
BACKGROUND . . . . .	2
OBJECTIVES . . . . .	3
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW . . . . .	3
SEARCH METHODS FOR IDENTIFICATION OF STUDIES . . . . .	3
METHODS OF THE REVIEW . . . . .	4
DESCRIPTION OF STUDIES . . . . .	4
METHODOLOGICAL QUALITY . . . . .	5
RESULTS . . . . .	5
DISCUSSION . . . . .	7
AUTHORS' CONCLUSIONS . . . . .	7
POTENTIAL CONFLICT OF INTEREST . . . . .	7
ACKNOWLEDGEMENTS . . . . .	7
SOURCES OF SUPPORT . . . . .	7
REFERENCES . . . . .	8
TABLES . . . . .	9
Characteristics of included studies . . . . .	9
Characteristics of excluded studies . . . . .	12
ANALYSES . . . . .	13
Comparison 01. EPO i.v. versus placebo i.v. . . . .	13
Comparison 02. EPO + iron versus iron . . . . .	13
Comparison 03. EPO s.c. versus EPO i.v. . . . .	13
INDEX TERMS . . . . .	14
COVER SHEET . . . . .	14
Analysis 01.01. Comparison 01 EPO i.v. versus placebo i.v., Outcome 01 Self-Report Symptom Inventory 90 Items - Revised (SCL-90-R) . . . . .	15
GRAPHS AND OTHER TABLES . . . . .	15
Analysis 01.02. Comparison 01 EPO i.v. versus placebo i.v., Outcome 02 Items of the Blues Questionnaire showing statistically significant difference by day 5 . . . . .	15
Analysis 01.03. Comparison 01 EPO i.v. versus placebo i.v., Outcome 03 Haemoglobin (g/dL) within 2 weeks after treatment . . . . .	16
Analysis 01.04. Comparison 01 EPO i.v. versus placebo i.v., Outcome 04 Haematocrit (%) within 2 weeks after treatment . . . . .	16
Analysis 02.01. Comparison 02 EPO + iron versus iron, Outcome 01 Use of blood transfusions . . . . .	17
Analysis 02.02. Comparison 02 EPO + iron versus iron, Outcome 02 Lactating . . . . .	17
Analysis 02.03. Comparison 02 EPO + iron versus iron, Outcome 03 Thromboembolic complications . . . . .	18
Analysis 02.04. Comparison 02 EPO + iron versus iron, Outcome 04 Anaphylactic/serious reaction . . . . .	18
Analysis 02.05. Comparison 02 EPO + iron versus iron, Outcome 05 Length of postnatal hospital stay, median (days) . . . . .	18
Analysis 02.06. Comparison 02 EPO + iron versus iron, Outcome 06 Haemoglobin (g/dL) within 2 weeks after treatment . . . . .	19
Analysis 02.07. Comparison 02 EPO + iron versus iron, Outcome 07 Haemoglobin increase (%) within 2 weeks after treatment . . . . .	20
Analysis 02.08. Comparison 02 EPO + iron versus iron, Outcome 08 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment . . . . .	21
Analysis 02.09. Comparison 02 EPO + iron versus iron, Outcome 09 Haemoglobin (g/dL) median . . . . .	21
Analysis 02.10. Comparison 02 EPO + iron versus iron, Outcome 10 Haematocrit (%) within 2 weeks after treatment . . . . .	22
Analysis 02.11. Comparison 02 EPO + iron versus iron, Outcome 11 Haematocrit > 35% 2 weeks after treatment . . . . .	22
Analysis 02.12. Comparison 02 EPO + iron versus iron, Outcome 12 Haematocrit (%) > 2 weeks to 6 weeks after treatment . . . . .	23
Analysis 02.13. Comparison 02 EPO + iron versus iron, Outcome 13 Haematocrit (median %) . . . . .	23
Analysis 03.01. Comparison 03 EPO s.c. versus EPO i.v., Outcome 01 Adverse effects reported for EPO . . . . .	23

Analysis 03.02. Comparison 03 EPO s.c. versus EPO i.v., Outcome 02 Haemoglobin (g/dL) within 2 weeks after treatment . . . . .	24
Analysis 03.03. Comparison 03 EPO s.c. versus EPO i.v., Outcome 03 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment . . . . .	25
Analysis 03.04. Comparison 03 EPO s.c. versus EPO i.v., Outcome 04 Haematocrit (%) within 2 weeks after treatment	26
Analysis 03.05. Comparison 03 EPO s.c. versus EPO i.v., Outcome 05 Haematocrit (%) > 2 weeks to 6 weeks after treatment . . . . .	26

# Treatment for women with postpartum iron deficiency anaemia (Review)

Dodd J, Dare MR, Middleton P

## This record should be cited as:

Dodd J, Dare MR, Middleton P. Treatment for women with postpartum iron deficiency anaemia. *Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD004222. DOI: 10.1002/14651858.CD004222.pub2.

**This version first published online:** 18 October 2004 in Issue 4, 2004.

**Date of most recent substantive amendment:** 28 July 2004

## ABSTRACT

### Background

Postpartum anaemia is associated with breathlessness, tiredness, palpitations and maternal infections. Blood transfusions or iron supplementation have been used in the treatment of iron deficiency anaemia. Recently other anaemia treatments, in particular erythropoietin therapy, have also been used.

### Objectives

To assess the clinical effects of treatments for postpartum anaemia, including oral, intravenous or subcutaneous iron/folate supplementation and erythropoietin administration, and blood transfusion.

### Search strategy

We searched the Cochrane Pregnancy and Childbirth Group trials register (30 May 2004), the Cochrane Central Register of Controlled Trials (*The Cochrane Library*, Issue 1, 2003), MEDLINE (1966 to March 2003), EMBASE (1980 to March 2003), Current Contents and ACP Journal Club (from inception to March 2003).

### Selection criteria

Randomised controlled trials (RCTs) comparing therapy for postpartum iron deficiency anaemia (oral, intravenous or subcutaneous administration of iron, folate, erythropoietin or blood transfusion) with placebo, another treatment or no treatment.

### Data collection and analysis

Two reviewers independently assessed trial quality and extracted data.

### Main results

Six included RCTs involving 411 women described treatment with erythropoietin or iron as their primary interventions. No RCTs were identified that assessed treatment with blood transfusion. Few outcomes relating to clinical maternal and neonatal factors were reported: studies focused largely on surrogate outcomes such as haematological indices. Overall, the methodological quality of the included RCTs was reasonable; however, their usefulness in this review is restricted by the interventions and outcomes reported.

When compared with iron therapy only, erythropoietin increased the likelihood of lactation at discharge from hospital (1 RCT,  $n = 40$ ; relative risk (RR) 1.90, 95% confidence interval (CI) 1.21 to 2.98). No apparent effect on need for blood transfusions was found, when erythropoietin plus iron was compared to treatment with iron only (2 RCTs,  $n = 100$ ; RR 0.20, 95% CI 0.01 to 3.92), although the RCTs may have been of insufficient size to rule out important clinical differences. Haematological indices (haemoglobin and haemocrit) showed some increases when erythropoietin was compared to iron only, iron and folate, but not when compared with placebo.

### Authors' conclusions

There is some limited evidence of favourable outcomes for treatment of postpartum anaemia with erythropoietin. However, most of the available literature focuses on laboratory haematological indices, rather than clinical outcomes. Further high-quality trials assessing the treatment of postpartum anaemia with iron supplementation and blood transfusions are required. Future trials may also examine the significance of the severity of anaemia in relation to treatment, and an iron-rich diet as an intervention.

## PLAIN LANGUAGE SUMMARY

Erythropoietin, a hormone, may help to treat women who develop anaemia after giving birth, but there may be rare adverse events

Women with anaemia after childbirth may feel tired and breathless and are at risk of infection. Traditional treatments include iron supplementation and blood transfusion for severe anaemia. A hormone, erythropoietin, may help improve iron levels in the blood and the woman's ability to lactate. However, rare adverse events (damage to red blood cells) have been reported. No studies examined the effects of oral iron supplementation alone, the most common treatment for this type of anaemia, or blood transfusions as treatments for women with anaemia after childbirth. More research, particularly of simple interventions such as oral iron supplementation, is required.

## BACKGROUND

Anaemia after the birth of a baby (postpartum anaemia) is a common problem throughout the world and for most women is self limiting, resolving within a week (Atkinson 1994). For some women however, particularly in resource-poor countries, it is a major cause of maternal morbidity (poor health) and mortality (Ekanem 1996; Harrison 1989; Kumar 1989; Rosenfield 1989). In this setting, anaemia may result from inadequate dietary intake, parasitic infection or malaria, and may be exacerbated by the physiological effects of pregnancy and blood loss at the time of birth (WHO 1999). Worldwide, anaemia contributed to approximately 20% of the 515,000 maternal deaths in 1995 (WHO 1999). Anaemia is often associated with other markers on blood testing of low iron stores in the body. During pregnancy most women show a fall in haemoglobin concentration as part of a normal response to pregnancy, where there is an increase in plasma and the circulating blood volume, which protects the woman from the blood loss associated with birth. The generally accepted threshold for anaemia in nonpregnant women is a haemoglobin concentration of less than 12 g/dL (WHO 2001). However, it should be noted that this is a value statistically derived from deviations from the population mean, and does not necessarily mean that the woman will have clinical symptoms associated with anaemia (WHO 2001).

Anaemia in the postpartum period may be associated with an increased prevalence of breathlessness, tiredness, palpitations and maternal infections, particularly of the urinary tract (Gibbs 1980; Vora 1998). Such symptoms may cause women to experience difficulty caring for their baby, and may influence the emotional bond the mother has with her baby (Gilbert 1987).

Blood transfusions have been used in the treatment of postpartum anaemia, but there are risks associated with its use. These include reactions secondary to contamination (most commonly with leukocytes or red blood cells), infections (particularly with hepatitis, Human Immunodeficiency Virus (HIV) and cytomegalovirus), fluid overload, allergic reactions, lung injury and air embolism (Klapholz 1990; Naef 1995a; Nolan 1991; Skolnick 1992; Waymack 1990). Immunological reactions may be 'minor'

and include fever, chills, urticaria (skin rash and/or hives), or more severe, including acute haemolysis (breakdown of red blood cells) arising from administration of incompatible blood (Naef 1995b). Hepatitis C infection is estimated to occur in approximately 0.1% of all patients who receive blood. The cost of blood transfusions includes extensive costs of screening the blood for infection, storage and sterile administration of blood products, all of which may generate increased financial burden, particularly in under-resourced countries (Ekanem 1996).

Given the risks of blood transfusion and financial constraints, attention has been directed towards other forms of treatment of anaemia such as iron supplements and erythropoietin therapy, both oral (by mouth) and parenteral (by intravenous, intramuscular or subcutaneous injection). Erythropoietin is a hormone that is produced by the body and acts to stimulate red blood cell production.

Oral iron therapy has been used for centuries as a treatment of iron deficiency anaemia (Dudrick 1986), and has been used to treat iron deficiency anaemia during pregnancy (Mahomed 2003). The use of oral iron therapy is associated with some side-effects, including constipation, nausea and gastric irritation. When given by injection, iron has been associated with pain and redness (erythema) at the injection site, and rarely anaphylactic reaction, characterised by itching, redness and in severe cases angioedema (swelling), vascular collapse, bronchospasm (constriction of the airways) and shock. Erythropoietin (EPO) therapy is a relatively recently identified alternative to blood transfusions for the treatment of iron deficiency anaemia, and has been used extensively in the treatment of anaemia associated with renal (kidney) disease. There are a few case reports of EPO therapy in people who have refused blood transfusions on religious grounds, with positive outcomes (Davis 1990), thus highlighting the potential use of EPO in the treatment of other forms of iron deficiency anaemia. Adverse effects of EPO treatment include mild flu-like symptoms such as sore throat, cough, fever, muscle pains and weakness, headache and fatigue. Uncommon, but more serious adverse effects include hypertension (high blood pressure) and seizures and, more recently, pure red-cell aplasia (Casadevall 2002).

## OBJECTIVES

To evaluate the effects of treatments for postpartum anaemia, including oral, intramuscular, intravenous or subcutaneous iron/folate supplementation and erythropoietin administration, and blood transfusion.

## CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

### Types of studies

All published, unpublished and ongoing randomised controlled trials with reported data which compared outcomes for women who were administered therapy for postpartum iron deficiency anaemia with outcomes in women who were given a placebo, another treatment or no treatment.

### Types of participants

Women with a haemoglobin value of less than 12 g/dl (WHO 2001) up to six weeks after birth.

### Types of intervention

The administration of therapy (iron, folate, erythropoietin or blood transfusion) by oral, intravenous, intramuscular or subcutaneous routes for postpartum iron deficiency anaemia when compared with placebo, another treatment or no treatment, started in the first six weeks after birth.

### Types of outcome measures

#### *Maternal outcomes*

- (1) Use of blood transfusion(s) - when the treatment has been with iron, folate or erythropoietin.
- (2) Fatigue (as reported by the women - verbalisation of fatigue or lack of energy and inability to maintain usual routines; and as defined by trial authors).
- (3) Tolerance for physical load (as defined by the trial authors).
- (4) Dyspnoea (as reported by the women - distressful sensation of uncomfortable breathing; and as defined by the trial authors).
- (5) Tachypnoea (increase in respiratory rate as defined by trial authors).
- (6) Tachycardia (heart rate greater than 100 beats per minute or as defined by trial authors).
- (7) Palpitations (as reported by women - pounding or racing of the heart; and as defined by trial authors).
- (8) Orthostatic dizziness (as reported by the women - a sensation on standing of faintness and whirling or inability to maintain balance in a standing or seated position; and as defined by trial authors).
- (9) Syncope (transient loss of consciousness and postural tone caused by reduced cerebral blood flow, and often preceded by a sensation of light headedness, as defined by trial authors).
- (10) Headache (as defined by trial authors).

- (11) Not breastfeeding:
  - (a) at hospital discharge;
  - (b) six weeks postpartum;
  - (c) six months postpartum.
- (12) Infection up to six weeks postpartum:
  - (a) urinary tract infection requiring treatment;
  - (b) endometritis requiring treatment.
- (13) Psychological wellbeing (measured by the 'Blues Questionnaire', 'Self-report symptom inventory 90 [SCL-90-R]' or similar questionnaire).

#### *Use of health resources*

- (1) Length of postnatal hospital stay.
- (2) Readmission to hospital after primary hospital discharge.
- (3) Costs of treatment:
  - (a) for the woman;
  - (b) for the health service.

#### *Maternal satisfaction with care*

- (1) Woman satisfied with care.

#### *Adverse effects of treatment*

- (1) Thromboembolic complications:
  - (a) deep venous thrombosis (blood clots in the veins of the leg) requiring treatment;
  - (b) pulmonary embolism (blood clots in the lung).
- (2) Anaphylactic reactions (characterised by itching, angioedema (swelling) and in severe cases, vascular collapse, bronchospasm (constriction of the airways) and shock).
- (3) Gastrointestinal symptoms when the treatment is iron supplementation (diarrhoea, constipation, nausea, heartburn and upper abdominal discomfort).
- (4) When the intervention has been treatment with erythropoietin: mild flu-like symptoms (sore throat, cough, fever, muscular pains and weakness, chills, respiratory symptoms, headache, and fatigue), hypertension (blood pressure persistently exceeding 140/90 mm Hg), hypertensive encephalopathy (headache, convulsions and coma), seizures (focal or generalised), hyperkalaemia (plasma concentration > 4.5 mmol/L or serum concentration > 4.9 mmol/L) and hyperphosphataemia (> 1.50 mmol/L).
- (5) Viral infection - as shown by positive serology on blood testing.

## SEARCH METHODS FOR IDENTIFICATION OF STUDIES

See: methods used in reviews.

We searched the Cochrane Pregnancy and Childbirth Group trials register by contacting the trials search co-ordinator (30 May 2004).

The Cochrane Pregnancy and Childbirth Group's trials register is maintained by the Trials Search Co-ordinator and contains trials identified from:

1. quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
2. monthly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major conferences;
4. weekly current awareness searches of a further 37 journals.

Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Search strategies for identification of studies' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.

Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Coordinator searches the register for each review using these codes rather than keywords.

In addition, we searched the Cochrane Controlled Trials Register (March 2003), MEDLINE (1966 to March 2003), EMBASE (1980 to March 2003), Current Contents and ACP journal club (1991 to March 2003) using the MeSH headings 'anemia', 'postpartum', 'puerperium', 'treatment', 'treatment - outcome', 'therapy', 'drug - therapy', 'transfusion'.

We also searched the citation lists of relevant publications, review articles and included studies.

## METHODS OF THE REVIEW

Two reviewers (Jodie Dodd and Marianna Dare) performed the search and selection of trials for inclusion in the review, with discrepancies resolved by discussion. Excluded studies are detailed in the 'Characteristics of excluded studies' table. Included studies were assessed for quality and methodological details without consideration of the results. Data were extracted separately by two of the three authors and double entered. Discrepancies were resolved by discussion. There was no blinding of authorship.

For all included randomised trials, we assigned quality scores for concealment of allocation to each trial, as described in section VI of the Cochrane Reviewers' Handbook (Clarke 2003):

- A = adequate;
- B = unclear;
- C = inadequate;
- D = not used.

Completeness of follow up was assessed for each included study as follows:

- A = less than 3% of participants excluded;
- B = 3% to 9.9% of participants excluded;
- C = 10% to 19.9% of participants excluded;
- D = 20% or more of the participants excluded;

E = unclear.

For blinding of assessment of outcome:

A = neither the investigator (outcome assessor) nor participant knew or were likely to guess the allocated allotment;

B = either the investigator (outcome assessor) or participant knew the allocation. Or neither knew, but the outcome means that it is likely a significant portion of the participant's allocation could be easily identified;

C = no blinding - investigator (outcome assessor) and participant knew (or were likely to guess) the allocated treatment;

D = unclear.

Descriptive data included the authors, year of publication, setting, country, time span of trial, pretrial calculation of sample size and the number of participants randomised and analysed.

For dichotomous data, results for each study were expressed as relative risks with 95% confidence intervals and combined for meta-analysis with the RevMan Manager software (RevMan 2004). For continuous data we expressed results for each study as weighted mean differences with 95% confidence intervals. We used a random effects model.

We investigated heterogeneity in the data using the  $I^2$  statistic and cautiously explored it using sensitivity analyses ( $I^2 > 50\%$  was regarded as statistically significant heterogeneity).

Planned subgroup analyses were:

- (1) dose administered;
- (2) frequency of administration;
- (3) duration of treatment;
- (4) study setting - resource-poor versus resource-rich countries;
- (5) severity of anaemia at trial entry;
- (6) concurrent disease at trial entry (including HIV, sickle cell disease, thalassaemia).

We were unable to perform most of the planned subgroup analyses due to the small number of included trials. We explored results associated with route of treatment administration and duration of treatment for some outcomes when iron was compared with erythropoietin (*see* 'Graphs and tables'). Timing of outcome measurement varied across trials. To facilitate analyses, we grouped the results into two measurement periods, reflecting short- and longer-term effects: within the first two weeks after treatment, and between two weeks and six weeks after treatment.

## DESCRIPTION OF STUDIES

Thirteen studies describing treatment of postpartum anaemia were identified, with seven not meeting the selection criteria. We excluded two trials because of inadequate randomisation (Danko 1990; Huch 1992), one because it did not report on interventions defined as appropriate for inclusion in the review (Osmond 1953), two reported results on women who were not anaemic

(Mara 2001; Picha 1975), one combined pregnant and postpartum women with anaemia in the study population (Casparis 1996) and one summarised the results of trials that were reported in included studies (Zimmermann 1995).

The six included randomised controlled trials (RCTs) involved 411 women (Breyman 1996; Breyman 2000; Lebrecht 1995; Makrydimas 1998; Meyer 1995; Zimmermann 1994). Some of the RCTs reported on more than one intervention. Four RCTs compared treatment with erythropoietin and iron to treatment with iron only (Breyman 1996; Breyman 2000; Makrydimas 1998; Lebrecht 1995), one RCT compared treatment with erythropoietin to treatment with placebo (Meyer 1995), two RCTs compared different routes of erythropoietin administration (intravenous versus subcutaneous) (Breyman 1996; Zimmermann 1994), and one RCT compared erythropoietin given as one dose with that given as two doses (Zimmermann 1994). No RCTs were identified that described results of folate therapy or blood transfusion as an intervention.

In Breyman 1996, 300 units/kg of erythropoietin (EPO) were administered to women in the EPO group once, and in Breyman 2000, this dose was administered daily for four days. In Lebrecht 1995, 20,000 units of EPO were given to women as a single dose. In Makrydimas 1998, 200 units/kg of EPO were administered to women in the EPO group daily for 15 days. Meyer 1995 administered 10,000 units of EPO twice. In Zimmermann 1994, two doses of 150 units/kg were compared with a single dose of 300 units/kg of EPO.

All RCTs focused on haematological indices in their results, with limited information regarding clinical outcomes. Of the clinical outcomes described, use of blood transfusions was described by two RCTs (Breyman 2000; Makrydimas 1998), not lactating by one RCT (Makrydimas 1998), thromboembolic complications by two RCTs (Lebrecht 1995; Makrydimas 1998), serious reactions by two RCTs (Breyman 1996; Breyman 2000), and side-effects for erythropoietin by two RCTs (Lebrecht 1995; Zimmermann 1994).

Details of each RCT are given in the 'Characteristics of included studies' table.

## METHODOLOGICAL QUALITY

Three trials reported using sealed envelopes to allocate women to treatment groups (Breyman 1996; Breyman 2000; Zimmermann 1994). The remaining three studies, though stated to be randomised studies, were unclear in their method of concealment of allocation. All six trials were coded B for allocation concealment.

Blinding to intervention for either investigators or women did not appear to have occurred in any of the studies. Insufficient infor-

mation was provided to determine whether blinding of outcome assessors had occurred in any of the studies.

No losses to follow up were reported, except for Meyer 1995 who described a drop-out rate of over 20% (with no differences in dropout rate between the intervention and control groups).

## RESULTS

Included studies described treatment with erythropoietin or iron as their primary interventions. Women in both the intervention and control groups received iron supplementation in all studies except one (Meyer 1995). No studies were identified that described treatment with blood transfusion, and for each intervention there were only one or two studies that reported the same outcomes and thus had results that could be combined.

Few of the prespecified outcomes were reported by the studies regarding 'maternal outcomes', 'use of health resources', 'maternal satisfaction with care', and 'side-effects of treatment'.

The remainder of the results reported in the studies were blood indices. While these were not prespecified in the protocol as outcome measures that were of relevance to the population, we decided that to omit haematological outcomes altogether when reporting the results of the review would mean that much of the data reported by the studies would be lost. Thus we have presented the outcomes for the haematological studies as subsidiary outcomes reported by the reviewers in each section. The results are presented in dot point form to allow easier interpretation. The small number of women in the groups studied meant the confidence intervals were wide. Larger groups may have provided statistically significant results. Further details are provided in 'Graphs and tables'.

### (1) Any treatment versus placebo

#### *Intravenous (i.v.) erythropoietin (EPO) versus i.v. placebo*

##### *Maternal outcomes (see Other data tables)*

- For the Blues Questionnaire (used to assess postpartum depression), statistically significant increases were seen for the items 'able to concentrate', 'elated', 'happy', 'confident' and 'calm' when EPO was compared with placebo (Meyer 1995).

##### *Use of health resources*

- No data were provided for these outcomes.

##### *Maternal satisfaction with care*

- No data were provided for these outcomes.

##### *Adverse effects*

- No data were provided for these outcomes.

##### *Subsidiary outcomes - (as reported by the authors, not prespecified by reviewers)*



- No significant difference was observed in haemoglobin (weighted mean difference (WMD) 0.40 g/dL 95% confidence interval (CI) -0.26 to 1.06) or haematocrit (WMD 1.60% 95% CI -0.42 to 3.62) within two weeks after treatment (Meyer 1995; 71 women).

## (2) EPO versus any other treatment

### *EPO plus iron versus iron alone*

#### *Maternal outcomes*

- The relative risk (RR) for needing blood transfusion for EPO plus iron compared with iron only was 0.20; 95% CI 0.01 to 3.92 (100 women in two trials (Breyman 2000; Makrydimas 1998)).
- Women treated with EPO plus iron were more likely to be lactating when discharged from hospital than women treated with iron only (RR 1.90; 95% CI 1.21 to 2.98). This was reported by one trial describing 40 women (Makrydimas 1998).

#### *Use of health resources*

- No data were provided for these outcomes.

#### *Maternal satisfaction with care*

- No data were provided for these outcomes.

#### *Adverse effects*

- No adverse effects of treatment were seen in either the EPO + iron or iron alone groups (no thromboembolic complications reported in two trials (Breyman 2000; Makrydimas 1998; 96 women) and no anaphylactic reactions reported in three trials (Breyman 1996; Breyman 2000; Lebrecht 1995; 186 women).

#### *Subsidiary outcomes (as reported by the authors - not prespecified by reviewers)*

##### *Haemoglobin within two weeks after treatment*

- No difference was seen in haemoglobin within two weeks after treatment when EPO i.v. + iron was compared with oral or i.v. iron only (WMD 0.45 g/dL 95% CI -0.16 to 1.06; Breyman 1996; 60 women) or with oral and i.v. iron only (WMD 0.40 g/dL 95% CI -0.22 to 1.02; Lebrecht 1995; 36 women); or with i.v. iron (WMD 0.20% increase 95% CI -0.27% to 0.67%; Breyman 2000; 40 women).
- When i.v. EPO + iron was compared with oral iron only, however, there was an increase in haemoglobin (WMD 0.70% increase 95% CI 0.23 to 1.17; Breyman 2000; 40 women).
- When subcutaneous (s.c.) EPO + iron was compared with oral or i.v. iron only, there was a decrease in haemoglobin (-0.55 g/dL 95% CI -0.99 to -0.11; Breyman 1996; 60 women).

##### *Haemoglobin >2 weeks to 6 weeks after treatment*

- No differences were seen for EPO + iron versus iron only regardless of route - i.v. EPO + iron compared with oral or i.v. iron only (WMD 0.40 g/dL 95% CI -0.09 to 0.89; Breyman 1996; 60 women); s.c. EPO + iron compared with oral or i.v. iron only (WMD 0.30 g/dL 95% CI -0.34 to 0.94; Breyman 1996; 60 women); or i.v. EPO + iron compared with oral and i.v. iron (WMD 0.40 g/dL 95% CI -0.20 to 1.00).

##### *Haematocrit (%) within 2 weeks after treatment*

- Haematocrit values were greater with EPO + iron compared with iron (either i.v. or oral) in Breyman 2000: WMD 2.30% 95% CI 1.89 to 2.71 compared with i.v. iron (40 women) and WMD 3.50% 95% CI 3.19 to 3.81 compared with oral iron (40 women).
- In contrast, no significant difference was seen when EPO + iron was compared with oral and i.v. iron (WMD 1.50% 95% CI -0.38 to 3.38; Lebrecht 1995; 36 women).

##### *Haematocrit (%) between two and six weeks after treatment*

- No significant difference was seen when EPO + iron was compared with oral and i.v. iron (WMD 0.10% 95% CI -3.06 to 3.26; Lebrecht 1995; 36 women)

## (3) Comparing routes of EPO administration - subcutaneous versus intravenous

### *Maternal outcomes*

- No data were available for these outcomes.

### *Use of health resources*

- No data were available for these outcomes.

### *Maternal satisfaction*

- No data were available for these outcomes.

### *Adverse effects*

- No adverse effects were reported when comparing different routes of erythropoietin administration in Zimmermann 1994 (95 women).

### *Subsidiary outcomes (as reported by authors, not an outcome prespecified by reviewers)*

#### *Haemoglobin (g/dL) within two weeks after treatment:*

- No differences were seen between i.v. and s.c. routes within two weeks after treatment (WMD -0.34 g/dL 95% CI -0.94 to 0.26; Breyman 1996; Zimmermann 1994; total of 145 women). However statistically significant heterogeneity was noted in the i.v. versus s.c. comparison when EPO was given as one dose ( $I^2 = 70.7\%$ ). This may have been due to all women in Breyman 1996 receiving iron i.v. whereas in Zimmermann 1994, women received only oral iron supplementation.

#### *Haemoglobin (g/dL) between two weeks to six weeks after treatment:*

- Similarly no differences were seen later (WMD 0.02 g/dL 95% CI -0.27 to 0.32; Breymann 1996; Zimmermann 1994; total of 145 women).

*Haematocrit (%) within two weeks after treatment:*

- No difference was seen in the haematocrit value (WMD -0.48% 95% CI -1.83 to 0.86; Zimmermann 1994; 95 women).

*Haematocrit (%) between two weeks to six weeks after treatment:*

- Similarly no differences were seen later (WMD -0.72% 95% CI -1.66 to 0.21; Zimmermann 1994; 95 women).

## DISCUSSION

The methodological quality of the included studies is generally reasonable; however their usefulness in this review is restricted by the interventions and outcomes reported. There is very limited information relating to clinical outcomes in the included studies, despite extensive reporting of haematological indices.

Laboratory haemoglobin values may not directly reflect the woman's clinical state. It is unclear whether the women involved in the original studies were clinically symptomatic, and treatment of a woman's symptoms would seem more appropriate than treatment determined by an arbitrary level of haemoglobin or values from other haematological indices. A haemoglobin of less than 12 g/dL is a very conservative marker for iron deficiency anaemia, and many women may not experience symptoms (and therefore will not require treatment) at this level. Most studies in the review reported results for women with an haemoglobin of 10 g/dL or less, but did not categorise the severity of anaemia for analysis. Future studies would benefit from further assessment of the results of treatment according to the severity of anaemia.

The availability of blood transfusion and issues related to safety and sterility mean that it has a limited role in treatment for women in low- and middle-income countries. Similarly, erythropoietin is expensive and therefore not a realistic treatment option for those women at greatest risk of postpartum anaemia. Pure red cell aplasia has been reported as a rare adverse effect of erythropoietin, which is thought to be a consequence of antibody formation (Casadevall 2002). One of the companies marketing erythropoietin (as EPREX) has recommended that it should be given intravenously where possible, since this may reduce the risk of antibody formation (AADRB 2002).

As women in resource-poor countries are more likely to suffer morbidity and/or mortality secondary to postpartum anaemia, future trials should address the role of simple and cost-effective strategies to improve clinical outcomes for these women, in particular the role of oral iron therapy.

## AUTHORS' CONCLUSIONS

### Implications for practice

There is limited evidence for favourable outcomes for treatment of postpartum anaemia with erythropoietin, with small studies suggesting improved lactation, without an increase in side-effects. Haematological indices also appear to be favourably affected by treatment with erythropoietin, although how this relates to clinical practice is uncertain.

Information regarding the route of administration of erythropoietin is poor, as is information relating to outcomes following treatment with iron and blood transfusions. The possibility of rare adverse effects (such as red cell aplasia) needs to be monitored.

### Implications for research

Further high quality trials are required that assess the treatment of postpartum anaemia with oral and parental iron and blood transfusions and focus on clinically relevant outcomes such as maternal outcomes, safety and use of health resources. The effectiveness of common interventions such as iron-rich diet should also be assessed.

## POTENTIAL CONFLICT OF INTEREST

None known.

## ACKNOWLEDGEMENTS

As part of the pre-publication editorial process, this review has been commented on by two peers (an editor and referee who are external to the editorial team), one or more members of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.

Jacci Parsons (Department of Public Health, University of Adelaide) and Professor Crowther (Department of Obstetrics and Gynaecology, University of Adelaide) for their help designing and developing the protocol and the review.

## SOURCES OF SUPPORT

### External sources of support

- Department of Health and Ageing AUSTRALIA

### Internal sources of support

- Department of Obstetrics and Gynaecology, University of Adelaide AUSTRALIA

## REFERENCES

### References to studies included in this review

#### Breymann 1996 *{published data only}*

\* Breymann C, Zimmermann R, Huch R, Huch A. Use of recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anaemia. *European Journal of Clinical Investigation* 1996;**26**:123–30.

Krafft A, Breymann C, Huttner C, Huch R, Huch A. Erythropoietic quality of maternal milk. *Lancet* 1999;**354**(9180):778.

#### Breymann 2000 *{published data only}*

Breymann C, Richter C, Huttner C, Huch A. Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. *European Journal of Clinical Investigation* 2000;**30**:154–61.

#### Lebrecht 1995 *{published data only}*

Lebrecht A, Haberlin F, Eberhard J. Anemia in puerperium: parenteral iron substitution renders erythropoietin therapy dispensable [Anämie im Wochenbett: parenterale Eisensubstitution macht Erythropoietin-Therapie entbehrlich]. *Geburtshilfe und Frauenheilkunde* 1995;**55**(3):167–70.

#### Makrydimas 1998 *{published data only}*

Makrydimas G, Lolis D, Lialios G, Tsiara S, Georgiou I, Bourantas K. Recombinant human erythropoietin treatment of postpartum anaemia, preliminary results. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1998;**81**:27–31.

#### Meyer 1995 *{published data only}*

Meyer J, Eichhorn K, Vetter K, Christen S, Schleusner E, Klos A, et al. Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well?. *Journal of Perinatal Medicine* 1995;**23**:99–109.

#### Zimmermann 1994 *{published data only}*

Zimmermann R, Breymann C, Huch R, Huch A. rHuEPO in the treatment of postpartum anemia: subcutaneous versus intravenous administration. *Clinical Investigation* 1994;**72**(6 Suppl):S25–30.

### References to studies excluded from this review

#### Casparis 1996

Casparis D, Del Carlo P, Branconi F, Grossi A, Merante D, Gafforio L. Effectiveness and tolerance of oral doses of liquid ferrous gluconate in iron deficiency anaemia during pregnancy and in the immediate postnatal period: comparisons with other liquid or solid formulations containing bivalent or trivalent iron. *Minerva Ginecologica* 1996;**48**:511–8.

#### Danko 1990

Danko J, Huch R, Huch A. Epoetin alfa for treatment of postpartum anaemia. *Lancet* 1990;**335**:737–8.

#### Huch 1992

Huch A, Eichhorn K, Danko J, Lauener P, Huch R. Recombinant human erythropoietin in the treatment of postpartum anemia. *Obstetrics & Gynecology* 1992;**80**:127–31.

#### Mara 2001

Mara M, Zivny J, Eretova V, Kvasnicka J, Kuzel D, Umlaufova A, et al. Changes in markers of anemia and iron metabolism and how they

are influenced by antianemics in postpartum period. *Acta Obstetrica Gynecologica Scandinavica* 2001;**80**:142–8.

#### Osmond 1953

Osmond TG. Post-partum anaemia, a practical treatment. *Practitioner* 1953;**171**:77–80.

#### Picha 1975

Picha E. A new direction for iron therapy [Ein neuer Weg der Eisentherapie]. *Geburtshilfe und Frauenheilkunde* 1975;**35**(10):792–5.

#### Zimmermann 1995

Zimmermann R, Breymann C, Richter C, Huch R, Huch A. rHuEPO treatment of postpartum anaemia. *Journal of Perinatal Medicine* 1995;**23**:111–7.

### References to studies awaiting assessment

#### Huch 1990

Huch A, Huch R. EPO (rHuEPO) use in obstetrics. Proceedings of Ross Laboratories Special Conference, Hot Topics '90 in Neonatology; 1990 December 9–11; Washington DC, USA. 1990:79–80.

#### Krauss 1972

Krauss Von V, Nowotny D, Scharifzadeh AH. The effect and tolerance of oral iron therapy in child bed [Wirkung und Verträglichkeit oraler Eisenbehandlung im Wochenbett]. *Munchener Medizinische Wochenschrift* 1972;**114**(43):1877–9.

#### Mara 1999

Mara M, Eretova V, Zivny J, Kvasnicka J, Umlaufova A, Marova E. Anaemia and its treatment with oral antianaemic drugs in women during the post-partum period [Anemie a její léčba perorálními antianemiky u žen v poporodním období]. *Ceska Gynecologie* 1999;**64**(3):153–9.

### Additional references

#### AADRB 2002

Epoetin alfa and pure red cell aplasia. Australian Adverse Drug Reactions Bulletin; www.health.gov.au/tga/adr/aadrd/aadr0208.htm [accessed 16 December 2003] August 2002.

#### Atkinson 1994

Atkinson L, Baxley E. Post partum fatigue. *American Family Physician* 1994;**50**(1):113–8.

#### Casadevall 2002

Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. *New England Journal of Medicine* 2002;**346**(7):469–75.

#### Clarke 2003

Clarke M, Oxman A, editors. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. *Review Manager (RevMan)* [computer program]. Oxford, UK: The Cochrane Collaboration, 2003.

#### Davis 1990

Davis HP. Erythropoietin for patient refusing blood transfusion. *Lancet* 1990;**336**:384–5.

#### Dudrick 1986

Dudrick S, O'Donnell J, Matheny R, Unkel S, Raleigh D. Stimulation of hematopoiesis as an alternative to transfusion. *Southern Medical Journal* 1986;**79**(6):669–73.

**Ekanem 1996**

Ekanem A, Etuk S, Samson-Akpan U. The influence of cultural practice on puerperal anaemia. *International Journal of Gynecology & Obstetrics* 1996;**55**:169–70.

**Gibbs 1980**

Gibbs R. Clinical risk factors for puerperal infection. *Obstetrics & Gynecology* 1980;**55**(5 Suppl):178S–84S.

**Gilbert 1987**

Gilbert L, Porter W, Brown VA. Postpartum haemorrhage - a continuing problem. *British Journal of Obstetrics and Gynaecology* 1987;**94**:67–71.

**Harrison 1989**

Harrison K. Maternal mortality in developing countries. *British Journal of Obstetrics and Gynaecology* 1989;**96**:1–3.

**Klapholz 1990**

Klapholz H. Blood transfusion in contemporary obstetric practice. *Obstetrics & Gynecology* 1990;**75**(6):940–3.

**Kumar 1989**

Kumar R, Sharma A, Barik S, Kumar V. Maternal mortality inquiry in a rural community of North India. *International Journal of Gynecology & Obstetrics* 1989;**29**:313–9.

**Mahomed 2003**

Mahomed K. Iron supplementation in pregnancy (Cochrane Review). *The Cochrane Library* 2003, Issue 4. Art. No.: CD000117. DOI:[10.1002/14651858.CD000117.pub2](https://doi.org/10.1002/14651858.CD000117.pub2).

**Naef 1995a**

Naef R, Washburne J, Martin R, Magann E, Scanlon P, Morrison J. Hemorrhage associated with cesarean delivery: when is transfusion needed. *Journal of Perinatology* 1995;**15**(1):32–5.

**Naef 1995b**

Naef R, Morrison J. Transfusion therapy in pregnancy. *Clinical Obstetrics and Gynecology* 1995;**38**(3):547–57.

**Nolan 1991**

Nolan T, Gallup D. Massive transfusion: a current review. *Obstetrical and Gynecological Survey* 1991;**46**(5):289–95.

**RevMan 2004**

The Cochrane Collaboration. Review Manager (RevMan). 4.2.3. Oxford, UK: The Cochrane Collaboration, 2004.

**Rosenfield 1989**

Rosenfield A. Maternal mortality in developing countries - an ongoing but neglected 'epidemic'. *JAMA* 1989;**262**(3):376–9.

**Skolnick 1992**

Skolnick A. Transfusion medicine faces time of major 'challenges and changes'. *JAMA* 1992;**268**(6):697–700.

**Vora 1998**

Vora M, Gruslin A. Erythropoietin in obstetrics. *Obstetrical and Gynecological Survey* 1998; Vol. 53, issue 8:500–8.

**Waymack 1990**

Waymack J, Yurt R. The effect of blood transfusions on immune function. *Journal of Surgical Research* 1990;**48**:147–53.

**WHO 1999**

World Health Organization. *Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World Bank statement*. Geneva: WHO, 1999.

**WHO 2001**

World Health Organization, United Nations Children's Fund, United Nations University. *Iron deficiency anaemia; Assessment, Prevention and Control; A guide for programme managers*. Geneva: World Health Organization, 2001.

\*Indicates the major publication for the study

## TABLES

### Characteristics of included studies

Study	Breyman 1996
Methods	Randomised single centre study. Allocation concealment: sealed envelopes.
Participants	90 women. Inclusion criteria: postpartum haemoglobin < 10.0 g/ dL 48-72 h after delivery, normal cardiac and renal function, oral iron substitution during pregnancy. Exclusion criteria: pregnancy anaemia, peripartal infection, peripartal blood transfusion, haematological disease, previous myelosuppressive medications, history of thromboembolism, haemosiderosis, iron intolerance or rheumatoid polyarthritis.
Interventions	Group 1 (n = 30): saccharated iron 100mg, once i.v. Oral iron sulphate (160 mg elemental iron per day) and folic acid 0.7 mg per day for 6 weeks. Group 2 (n = 30): rhEPO 300 U/kg once s.c. Saccharated iron 100 mg once i.v. and oral iron sulphate (160 mg elemental iron per day) and folic acid 0.7 mg per day for 6 weeks.

## Characteristics of included studies (Continued)

	Group 3 (n = 30): rhEPO 300 U/kg once i.v., saccharated iron 100 mg once i.v., oral iron sulphate (160 mg elemental iron per day) and folic acid (0.7 mg/day) for 6 weeks. Treatment started 48-72 h after birth.
Outcomes	Blood samples taken on days 1, 4, 14 and 42 after the start of therapy. Vital signs recorded daily until discharge. Blood indices: haemoglobin, packed cell volume, reticulocyte count, serum iron and transferrin concentrations, serum ferritin concentration, C-reactive protein concentration.
Notes	Some results have been extracted from graphs presented in the paper.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Breymann 2000</b>
Methods	Randomised, placebo-controlled single-centre study. Allocation concealment: sealed envelopes containing numbers allocated to one of three groups.
Participants	60 postpartum women (divided into 3 groups of 20). Inclusion criteria: haemoglobin < 10 g/ dL 24-72 h after delivery. Exclusion criteria: pregnancy anaemia or anaemia prior to delivery, peripartur blood transfusion, anaemia as a result of causes other than blood loss, history of thromboembolism, signs of infection with a rectal temperature > 38.5 degrees, history of seizures, alcohol and/or drug abuse, renal or hepatic dysfunction, previous myelosuppressive medication, haemosiderosis, history of iron intolerance, and rheumatoid polyarthritis.
Interventions	Placebo refers to rhEPO only, all women received iron therapy. Group 1 (n = 20): rhEPO 300 U/kg body weight daily i.v. on days 1-4 and iron sucrose 200 mg i.v. daily. Group 2 (n = 20): rhEPO placebo (saline i.v.) and iron sucrose as per group 1. Group 3 (n = 20); (control): oral elemental iron sulphate (80 mg) and folic acid one hour before meals on an empty stomach.
Outcomes	Blood indices (taken prior to treatment and on days 4, 7 and 14): absolute reticulocyte count, haematocrit and haemoglobin and red cell indices, iron status markers (serum ferritin, iron, transferrin), serum EPO, CRP, vitamin B12 and folic acid levels. Other: vital signs and the incidence and severity of serious or unusual adverse events.
Notes	
Allocation concealment	B – Unclear

<b>Study</b>	<b>Lebrecht 1995</b>
Methods	Randomised, placebo-controlled single centre study. Allocation concealment: not stated.
Participants	36 women. Inclusion criteria: Hb < 9 g/dL on day two postpartum, after birth of a healthy child at least 38 weeks gestation. Exclusion criteria: anaemia from other causes, caesarean at delivery, cardiovascular illness, history of thromboembolic disease, infection, alcohol or drug dependence, blood transfusions, and renal or hepatic impairment.
Interventions	Group 1 (n = 24): given 20,000 IE rHuEPO i.v.. Group 2 (n = 12): placebo. For both groups, injections were administered on the second day postpartum. Both groups received iron i.v. on day 2, and oral iron for 4 weeks thereafter.
Outcomes	Blood samples taken immediately before therapy and on days 3, 4, 7, 14 and 28. Haemoglobin, haematocrit, erythrocyte count, reticulocytes, WCC, platelets, ferritin, transferrin saturation, and biochemical parameters were measured. On days 2, 7, 14 and 28 a survey regarding quality of life was filled out by participants.

## Characteristics of included studies (Continued)

	On days 2 and 28 the following clinical parameters were analysed: blood pressure, pulse, temperature.
Notes	It is unclear from the text of the article whether the results have been expressed as means and standard deviations, however, for the purpose of this review, we have interpreted the results as means and standard deviations.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Makrydimas 1998</b>
Methods	Randomised, single centre study. Allocation concealment: not stated.
Participants	40 women on the first day following birth. Inclusion criteria: Hb levels < 10 g/dl on day 1 postpartum, age 19-44 years, absence of serious illness including pre-eclampsia.
Interventions	Group 1 (n = 20): rHuEPO 200 IU/kg/day s.c. for 15 days, oral iron 200 mg/day for 40 days and folic acid 5 mg/day for 40 days. Group 2 (n = 20): Iron 200 mg/day and folic acid 5 mg/day for (both orally) for 40 days.
Outcomes	Blood samples were taken before birth and on days 1, 3, 5, 10, 15 and 40 postdelivery. Blood indices measured: haemoglobin, haematocrit, platelets, electrolytes, creatinine, serum iron, ferritin, total iron binding capacity, B12, folic acid, liver and renal function tests. Serum EPO levels. Clinical indices: temperature, blood pressure, subjective symptoms (side-effects - flu-like symptoms) and ECG (on days 1, 15 and 40). Ability to lactate and psychological wellbeing were noted.
Notes	Many of the results have been expressed as medians.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Meyer 1995</b>
Methods	Randomized, double-blind, placebo-controlled multicentre study. Allocation concealment: not stated.
Participants	90 (71) women postpartum. Inclusion criteria: women with a haemoglobin of less than 10 g/dl.
Interventions	Intervention referred to rhEPO. Intervention group (n = 35): EPREX 10,000 IU i.v. at 24 hours. Control group (n = 36): placebo i.v. at 24 hours.
Outcomes	On day 5 postpartum the haemoglobin level was measured. Psychopathology was measured using two questionnaires; the "Blues Questionnaire" during the first five consecutive days postpartum and the "SCL-90-R", used on the 5th day postpartum, before discharge from the hospital and at the time of presumed peak of mood changes shortly after delivery.
Notes	There was a relatively high drop-out rate of more than 20% (number of women analysed was 71). Drop-outs were due to withdrawal of consent or transferral of the child to an intensive care unit. Some data were extracted from graphs.
Allocation concealment	B – Unclear

<b>Study</b>	<b>Zimmermann 1994</b>
Methods	Randomised study. Allocation concealment: sealed envelopes.
Participants	95 women postpartum. Inclusion criteria: Hb < 10 g/dl within 3 days after birth, stable cardiac function and normal renal function (urine output > 1 ml per hour).

Exclusion criteria: high BP, pre-eclampsia or eclampsia, fever > 38.0 degrees, peripartum blood transfusions, oncologic or haematologic disease, myelosuppressive medications, history of thromboembolic events, treatment with other cytokines.

Interventions	Group 1 (n = 26): rHuEPO 150 U/kg body weight s.c. once daily for two consecutive days. Group 2 (n = 25): rHuEPO 150 U/kg body weight i.v. once daily for two consecutive days. Group 3 (n = 22): rHuEPO 300 U/kg body weight s.c. once only. Group 4 (n = 22): rHuEPO 300 U/kg body weight i.v. once only. All women received oral iron supplements (80 mg ferrous sulphate) and folic acid (0.35 mg) twice daily, regardless of iron supplementation during pregnancy. Therapy was begun 72 hours after birth at the latest.
Outcomes	Blood was taken at day 0, day 4, day 14 and day 42. Blood indices measured: haemoglobin, haematocrit, platelets, reticulocytes, CRP, ferritin. Clinical measurements: blood pressure, temperature, lactation during the first 5 days.
Notes	Reports results of different concentrations and routes of administration of erythropoietin rather than EPO versus other methods of treatment.
Allocation concealment	B – Unclear
BP: blood pressure CRP: C-reactive protein ECG: electrocardiogram EPO: erythropoietin h: hours Hb: haemoglobin IU (and IE): international units i.v.: intravenous rhEPO or rHuEPO: recombinant human erythropoietin s.c.: subcutaneous WCC: white cell count	

## Characteristics of excluded studies

Study	Reason for exclusion
Casparis 1996	Population combined women with anaemia during pregnancy and postpartum anaemia.
Danko 1990	Trial was quasi-randomised.
Huch 1992	Trial was quasi-randomised.
Mara 2001	Population reported in the study included women who were not anaemic.
Osmond 1953	The intervention focuses on crude liver extract, an intervention not prespecified for inclusion.
Picha 1975	The study assessed the usefulness of iron therapy in prevention, not treatment, of postpartum anaemia.
Zimmermann 1995	All three trials reported by the trials are reported in other included studies.

## ANALYSES

### Comparison 01. EPO i.v. versus placebo i.v.

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Self-Report Symptom Inventory 90 Items - Revised (SCL-90-R)			Other data	No numeric data
02 Items of the Blues Questionnaire showing statistically significant difference by day 5			Other data	No numeric data
03 Haemoglobin (g/dL) within 2 weeks after treatment	1	71	Weighted Mean Difference (Random) 95% CI	0.40 [-0.26, 1.06]
04 Haematocrit (%) within 2 weeks after treatment	1	71	Weighted Mean Difference (Random) 95% CI	1.60 [-0.42, 3.62]

### Comparison 02. EPO + iron versus iron

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Use of blood transfusions	2	100	Relative Risk (Random) 95% CI	0.20 [0.01, 3.92]
02 Lactating	1	40	Relative Risk (Random) 95% CI	1.90 [1.21, 2.98]
03 Thromboembolic complications	2	96	Relative Risk (Random) 95% CI	Not estimable
04 Anaphylactic/serious reaction	3	186	Relative Risk (Random) 95% CI	Not estimable
05 Length of postnatal hospital stay, median (days)			Other data	No numeric data
06 Haemoglobin (g/dL) within 2 weeks after treatment			Weighted Mean Difference (Random) 95% CI	Subtotals only
07 Haemoglobin increase (%) within 2 weeks after treatment			Weighted Mean Difference (Random) 95% CI	Subtotals only
08 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment			Weighted Mean Difference (Random) 95% CI	Subtotals only
09 Haemoglobin (g/dL) median			Other data	No numeric data
10 Haematocrit (%) within 2 weeks after treatment			Weighted Mean Difference (Random) 95% CI	Subtotals only
11 Haematocrit > 35% 2 weeks after treatment	1	60	Relative Risk (Random) 95% CI	1.45 [0.95, 2.23]
12 Haematocrit (%) > 2 weeks to 6 weeks after treatment			Weighted Mean Difference (Random) 95% CI	Subtotals only
13 Haematocrit (median %)			Other data	No numeric data

### Comparison 03. EPO s.c. versus EPO i.v.

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Adverse effects reported for EPO	1	95	Relative Risk (Random) 95% CI	Not estimable
02 Haemoglobin (g/dL) within 2 weeks after treatment	3	155	Weighted Mean Difference (Random) 95% CI	-0.34 [-0.94, 0.26]



03 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment	3	155	Weighted Mean Difference (Random) 95% CI	0.02 [-0.27, 0.32]
04 Haematocrit (%) within 2 weeks after treatment	2	95	Weighted Mean Difference (Random) 95% CI	-0.48 [-1.83, 0.86]
05 Haematocrit (%) > 2 weeks to 6 weeks after treatment	2	95	Weighted Mean Difference (Random) 95% CI	-0.72 [-1.66, 0.21]

## INDEX TERMS

### Medical Subject Headings (MeSH)

Anemia, Iron-Deficiency [blood; \*drug therapy]; Erythropoietin [\*therapeutic use]; Iron [\*therapeutic use]; Puerperal Disorders [blood; \*drug therapy]; Randomized Controlled Trials

### MeSH check words

Female; Humans

## COVER SHEET

<b>Title</b>	Treatment for women with postpartum iron deficiency anaemia
<b>Authors</b>	Dodd J, Dare MR, Middleton P
<b>Contribution of author(s)</b>	Jodie Dodd (JD) and Marianna Dare (MD) formulated and wrote the protocol; retrieved the papers and applied the study selection criteria. JD, MD and Philippa Middleton (PM) extracted the data; MD compiled the review and, together, JD, MD and PM analysed the data and wrote the review.
<b>Issue protocol first published</b>	2003/2
<b>Review first published</b>	2004/4
<b>Date of most recent amendment</b>	25 August 2004
<b>Date of most recent SUBSTANTIVE amendment</b>	28 July 2004
<b>What's New</b>	Information not supplied by author
<b>Date new studies sought but none found</b>	Information not supplied by author
<b>Date new studies found but not yet included/excluded</b>	Information not supplied by author
<b>Date new studies found and included/excluded</b>	30 May 2004
<b>Date authors' conclusions section amended</b>	Information not supplied by author
<b>Contact address</b>	Dr Jodie Dodd Maternal Fetal Medicine Subspecialist and NH&MRC Neil Hamilton Fairley Fellow School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology The University of Adelaide Women's and Children's Hospital 72 King William Road Adelaide South Australia

5006  
 AUSTRALIA  
 E-mail: jodie.dodd@adelaide.edu.au  
 Tel: +61 8 81617647  
 Fax: +61 8 81617652

**DOI** 10.1002/14651858.CD004222.pub2  
**Cochrane Library number** CD004222  
**Editorial group** Cochrane Pregnancy and Childbirth Group  
**Editorial group code** HM-PREG

**Analysis 01.01. Comparison 01 EPO i.v. versus placebo i.v., Outcome 01 Self-Report Symptom Inventory 90 Items - Revised (SCL-90-R)**

**GRAPHS AND OTHER TABLES**

**Self-Report Symptom Inventory 90 Items - Revised (SCL-90-R)**

Study	Item number	Erythropoietin	Placebo
Meyer 1995	20 - crying easily	Factor value - 1.4	Factor value - 1.47
Meyer 1995	24 - temper outbursts	Factor value - 0.65	Factor value - 0.61
Meyer 1995	30 - feeling blue	Factor value - 0.8	Factor value - 0.85
Meyer 1995	14 - low in energy	Factor value - 1.10	Factor value - 1.19
Meyer 1995	71 - feeling everything is an effort	Factor value - 0.72	Factor value - 0.80
Meyer 1995			
Meyer 1995			
Meyer 1995			
Meyer 1995			
Meyer 1995			

**Analysis 01.02. Comparison 01 EPO i.v. versus placebo i.v., Outcome 02 Items of the Blues Questionnaire showing statistically significant difference by day 5**

**Items of the Blues Questionnaire showing statistically significant difference by day 5**

Study	Item number	Erythropoietin	Placebo
Meyer 1995	Item 3 - able to concentrate	% yes - 40	% yes - 31
Meyer 1995	Item 5 - elated	% yes - 20	% yes - 19
Meyer 1995	Item 8 - alert	% yes - 33	% yes - 35
Meyer 1995	Item 12 - relaxed	% yes - 20	% yes - 33
Meyer 1995	Item 18 - happy	% yes - 40	% yes - 27
Meyer 1995	Item 19 - confident	% yes - 29	% yes - 28

## Items of the Blues Questionnaire showing statistically significant difference by day 5 (Continued)


Study	Item number	Erythropoietin	Placebo
Meyer 1995	Item 24 - lively	% yes - 16	% yes - 16
Meyer 1995	Item 28 - calm	% yes - 29	% yes - 28
Meyer 1995			
Meyer 1995			

### Analysis 01.03. Comparison 01 EPO i.v. versus placebo i.v., Outcome 03 Haemoglobin (g/dL) within 2 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 01 EPO i.v. versus placebo i.v.

Outcome: 03 Haemoglobin (g/dL) within 2 weeks after treatment




### Analysis 01.04. Comparison 01 EPO i.v. versus placebo i.v., Outcome 04 Haematocrit (%) within 2 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 01 EPO i.v. versus placebo i.v.

Outcome: 04 Haematocrit (%) within 2 weeks after treatment




### Analysis 02.01. Comparison 02 EPO + iron versus iron, Outcome 01 Use of blood transfusions

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 01 Use of blood transfusions




### Analysis 02.02. Comparison 02 EPO + iron versus iron, Outcome 02 Lactating

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 02 Lactating



### Analysis 02.03. Comparison 02 EPO + iron versus iron, Outcome 03 Thromboembolic complications

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 03 Thromboembolic complications

Study	EPO+iron n/N	iron n/N	Relative Risk (Random) 95% CI	Weight (%)	Relative Risk (Random) 95% CI
× Breymann 2000	0/40	0/20		0.0	Not estimable
× Lebrecht 1995	0/24	0/12		0.0	Not estimable
Total (95% CI)	64	32		0.0	Not estimable
Total events: 0 (EPO+iron), 0 (iron)					
Test for heterogeneity: not applicable					
Test for overall effect: not applicable					

### Analysis 02.04. Comparison 02 EPO + iron versus iron, Outcome 04 Anaphylactic/serious reaction

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 04 Anaphylactic/serious reaction

Study	EPO+iron n/N	iron n/N	Relative Risk (Random) 95% CI	Weight (%)	Relative Risk (Random) 95% CI
× Breymann 1996	0/60	0/30		0.0	Not estimable
× Breymann 2000	0/40	0/20		0.0	Not estimable
× Lebrecht 1995	0/24	0/12		0.0	Not estimable
Total (95% CI)	124	62		0.0	Not estimable
Total events: 0 (EPO+iron), 0 (iron)					
Test for heterogeneity: not applicable					
Test for overall effect: not applicable					

### Analysis 02.05. Comparison 02 EPO + iron versus iron, Outcome 05 Length of postnatal hospital stay, median (days)

#### Length of postnatal hospital stay, median (days)


Study	EPO+iron+folate (n=2)	iron+folate (n=20)
Makrydimas 1998	11 (range 10-16)	14 (range 11-19)

## Analysis 02.06. Comparison 02 EPO + iron versus iron, Outcome 06 Haemoglobin (g/dL) within 2 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 06 Haemoglobin (g/dL) within 2 weeks after treatment




# **Analysis 02.07. Comparison 02 EPO + iron versus iron, Outcome 07 Haemoglobin increase (%) within 2 weeks after treatment**

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 07 Haemoglobin increase (%) within 2 weeks after treatment




**Analysis 02.08. Comparison 02 EPO + iron versus iron, Outcome 08 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment**

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 08 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment



**Analysis 02.09. Comparison 02 EPO + iron versus iron, Outcome 09 Haemoglobin (g/dL) median**

**Haemoglobin (g/dL) median**

Study	Days after	EPO+iron+folate	Iron+folate
Makrydimas 1998	2d	7.8	7.3
Makrydimas 1998	4d	8.4	7.6
Makrydimas 1998	14d	10.3	8.9
Makrydimas 1998	39d	12.2	11.6




### Analysis 02.10. Comparison 02 EPO + iron versus iron, Outcome 10 Haematocrit (%) within 2 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 10 Haematocrit (%) within 2 weeks after treatment




### Analysis 02.11. Comparison 02 EPO + iron versus iron, Outcome 11 Haematocrit > 35% 2 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 11 Haematocrit > 35% 2 weeks after treatment




### Analysis 02.12. Comparison 02 EPO + iron versus iron, Outcome 12 Haematocrit (%) > 2 weeks to 6 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 02 EPO + iron versus iron

Outcome: 12 Haematocrit (%) > 2 weeks to 6 weeks after treatment



### Analysis 02.13. Comparison 02 EPO + iron versus iron, Outcome 13 Haematocrit (median %)

#### Haematocrit (median %)


Study	Days after	EPO+iron+folate	Iron+folate
Makrydimas 1998	2	25	22
Makrydimas 1998	4	27	24
Makrydimas 1998	14	32	27
Makrydimas 1998	39	37	35

### Analysis 03.01. Comparison 03 EPO s.c. versus EPO i.v., Outcome 01 Adverse effects reported for EPO

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 03 EPO s.c. versus EPO i.v.

Outcome: 01 Adverse effects reported for EPO




### Analysis 03.02. Comparison 03 EPO s.c. versus EPO i.v., Outcome 02 Haemoglobin (g/dL) within 2 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 03 EPO s.c. versus EPO i.v.

Outcome: 02 Haemoglobin (g/dL) within 2 weeks after treatment




### Analysis 03.03. Comparison 03 EPO s.c. versus EPO i.v., Outcome 03 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 03 EPO s.c. versus EPO i.v.

Outcome: 03 Haemoglobin (g/dL) > 2 weeks to 6 weeks after treatment




### Analysis 03.04. Comparison 03 EPO s.c. versus EPO i.v., Outcome 04 Haematocrit (%) within 2 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 03 EPO s.c. versus EPO i.v.

Outcome: 04 Haematocrit (%) within 2 weeks after treatment




### Analysis 03.05. Comparison 03 EPO s.c. versus EPO i.v., Outcome 05 Haematocrit (%) > 2 weeks to 6 weeks after treatment

Review: Treatment for women with postpartum iron deficiency anaemia

Comparison: 03 EPO s.c. versus EPO i.v.

Outcome: 05 Haematocrit (%) > 2 weeks to 6 weeks after treatment



(Continued ...)

(... Continued)

